Lipid Nanoparticles (LNPs) represent the core delivery vehicles for nucleic acid therapeutics and have achieved clinical milestones in mRNA vaccines, gene-editing therapies and beyond. Constructing efficient, precise screening workflows stands as a central component of LNP research and development. Essentially, LNP screening constitutes a multi-dimensional optimization system engineering endeavour, which must balance delivery efficiency, target specificity, biosafety and other key performance metrics. By harnessing technological innovations, researchers are overcoming two major bottlenecks: combinatorial explosion and poor in vitro–in vivo translation, laying a solid foundation for next-generation nucleic acid therapeutics. This article systematically elaborates technical strategies, critical evaluation metrics, cutting-edge advances and future trends in LNP screening.
Core Objectives and Challenges of LNP Screening
An ideal LNP carrier needs to complete a full cascade of delivery tasks: stable circulation in blood, accumulation in target tissues, cellular internalization, endosomal escape, intracellular nucleic acid release, and functional gene expression. This journey is impeded by multiple physiological barriers. The primary goal of LNP screening is to rapidly identify optimal formulations featuring high encapsulation efficiency, robust targeting capacity, low toxicity and favourable stability from an enormous pool of candidate compositions. Three prominent challenges remain:
Vast combinatorial space LNP performance is governed by lipid components (ionizable lipids, PEG-lipids, cholesterol, helper lipids, etc.), chemical architectures (alkyl chain length, branching number, functional moiety types, etc.) and physical parameters (particle size, surface charge, morphology, and more). If eight key parameters each carry ten alternative values, the total combinations reach 10⁹–10¹⁰. Conventional trial-and-error approaches cannot cover such a massive landscape.
Limited in vitro–in vivo correlation In vitro cellular assays fail to recapitulate complex physiological events including in vivo protein corona formation and organ biodistribution. Formulations exhibiting outstanding performance in mouse models may suffer compromised delivery efficacy when tested in non-human primates (NHPs).
Multi-objective trade-off dilemma Delivery efficiency and biological safety frequently involve inherent trade-offs. For instance, elevating the fraction of cationic lipids facilitates endosomal escape yet increases cytotoxicity; PEGylation prolongs systemic circulation but may hinder cellular uptake. Screening workflows are required to dynamically reconcile multiple conflicting performance indicators.
Core Technical Strategies for LNP Screening
Two complementary frameworks have matured for LNP screening: rational design and high-throughput combinatorial screening. Jointly, they drive the paradigm shift from empirical trial-and-error toward precision and high efficiency.
1. Bottom-up: Mechanism-driven rational design
Rational design builds upon in-depth mechanistic understanding. It enables directed functional optimization via precise tuning of LNP chemical structures and physical properties, centred on mastering pivotal delivery mechanisms:
pKa optimization of ionizable lipids: Lipids are engineered to remain neutral at physiological pH (7.4) to minimize toxicity and immunogenicity, while undergoing protonation in acidic endosomes (pH 5.0–6.0) to interact with endosomal membranes, triggering membrane disruption and nucleic acid release — the core mechanism underpinning LNP endosomal escape. For example, researchers at Zhejiang University established a library of ester-core degradable cationic lipids (nAcx-Cm). By modulating ester group counts and hydrophobic tail architectures, the pKa value was precisely tuned to approximately 6.0, balancing colloidal stability and endosomal escape capability.
Component simplification with enhanced functionality: Beyond the canonical four-component LNP platform (ionizable lipid, PEG-lipid, cholesterol, helper lipid), removing non-essential constituents improves tissue tropism. A three-component LNP system developed by Zhejiang University eliminated phospholipids and cholesterol, drastically boosting pulmonary mRNA delivery and mitigating off-target hepatic accumulation commonly observed with traditional LNPs.
Structure–activity relationship (SAR)-guided optimization: Defining quantitative correlations between lipid chemical structures and delivery behaviour. Evidence shows multi-branched lipids (4–6 branches) deliver cargo far more effectively than lipids with 1–3 branches, whereas single-tailed lipids confer superior colloidal stability compared to double-tailed analogues. Such rules support the de novo design of potent lipid molecules.
2. Top-down: High-throughput combinatorial screening
To tackle the unmanageable combinatorial space beyond the reach of rational design, high-throughput screening establishes a closed workflow of parallel formulation, multiplexed testing and quantitative profiling, enabling rapid evaluation of hundreds of candidate formulations. Key technical advances include:
Enabling parallel formulation technologies: Microfluidic mixing serves as the gold standard for LNP fabrication. Accurate regulation of flow rates, flow ratios and chip geometry enables scalable, reproducible small-batch preparation, yielding uniformly formulated samples for high-throughput campaigns. Researchers at Georgia Tech fabricated 72 LNPs with distinct chemical structures via microfluidics; after quality control, 45 stable formulations proceeded to downstream biological evaluation.
In vivo screening empowered by nucleic acid barcoding: Unique DNA or RNA barcode sequences are encapsulated within individual LNP formulations, permitting simultaneous profiling of in vivo behaviour for hundreds of candidates in a single experiment. Using barcode technology, Mayaan Therapeutics pooled 96 candidate LNPs for co-administration. Deep sequencing quantified formulation abundance across organs, rapidly identifying 21 lung-targeted candidates. This methodology also delivers notable advantages in NHP studies, substantially reducing animal usage, ethical concerns and experimental costs.
Construction of multi-modal detection pipelines: Integrating bioluminescence imaging, flow cytometry and single-cell RNA sequencing to enable comprehensive readouts spanning organ, cellular and molecular layers. Bioluminescence imaging quantifies mRNA delivery efficiency, while single-cell sequencing characterizes transfection heterogeneity across cell subtypes, supplying multi-dimensional datasets to guide formulation refinement.
Key Evaluation Metric Framework for LNP Screening
A high-performance LNP arises from balanced optimization across multiple dimensions. Screening programmes must implement a holistic evaluation framework covering physicochemical characteristics, in vitro functionality, in vivo potency and biosafety. Primary indicators are outlined below:
1. Physicochemical properties: Baseline screening criteria
Physicochemical traits directly determine LNP stability and in vivo fate, forming the threshold for preliminary formulation triage:
Encapsulation efficiency: Target value >95%. High encapsulation prevents free nucleic acids from systemic degradation and unwanted immune responses, serving as a prerequisite for effective delivery. Poor encapsulation causes cargo leakage, lowering therapeutic efficacy while elevating toxic risks.
Particle size and polydispersity index (PDI): Optimal hydrodynamic diameter ranges from 80–100 nm, facilitating endothelial extravasation and cellular uptake; a PDI <0.2 indicates narrow size distribution, guaranteeing consistent pharmacological performance and predictable in vivo behaviour across batches. As an illustration, 6Ac1-C12 LNPs exhibit uniform particle size and retain stability after 30 days of storage at 4 °C, offering a potential solution to cold-chain transportation challenges for mRNA therapeutics.
Zeta potential: Near-neutral or weakly negative charge under physiological pH (~0 mV) reduces non-specific interactions with plasma proteins and extends circulation half-life; protonation generates positive charge within acidic endosomes to promote endosomal escape.
Morphology and storage stability: Homogeneous solid spherical geometry is preferred; irregular particle architectures lead to low encapsulation efficiency and poorly controlled cargo release. Formulations must maintain constant particle size, minimal nucleic acid leakage and preserved biological activity during storage (4 °C or −20 °C).
2. In vitro performance: Core readout for preliminary screening
In vitro assays simulate intracellular delivery cascades to rapidly quantify transfection potency and cytotoxicity:
Transfection efficiency: Quantified via reporter gene expression (e.g., firefly luciferase), commonly reported as relative light units (RLU). Readouts exceeding 100,000 RLU generally indicate promising transfection potential.
Cytotoxicity: Assessed by CCK-8 and LDH release assays. Low cytotoxicity is mandatory for clinical translation; lead LNPs must sustain acceptable cell viability alongside robust transfection activity.
Endosomal escape efficiency: Detected using FRET analysis and fluorescence microscopy. Endosomal escape represents a major bottleneck for nucleic acid delivery; most conventional LNPs achieve merely 1–2% escape efficiency, and formulation optimization can markedly augment cytosolic cargo release.
3. In vivo efficacy and biosafety: Definitive validation benchmarks
In vivo testing constitutes the pivotal screening stage, simultaneously evaluating delivery potency, target selectivity and biocompatibility:
Targeted delivery efficiency: Quantification of target protein expression in desired organs or cell populations to assess tissue tropism and delivery magnitude. For instance, LNP-CAD9 achieves superior pulmonary delivery compared to the FDA-approved benchmark MC3/DOTAP platform, supporting its utility as an efficient carrier for lung-targeted therapeutics.
Biosafety profiling: Measurement of serum biochemistry parameters (hepatic and renal function, blood lipids), serum cytokine concentrations (IL-1RA, IL-10, etc.) to evaluate toxicity and immunogenicity. An optimal LNP induces negligible organ injury and only mild immune activation at therapeutically relevant doses.
Inter-species translatability: Consistency of delivery performance must be validated between murine models and non-human primates. Many LNPs displaying potent activity in mice underperform in NHPs; cross-species screening is essential to mitigate clinical translation failure.
Future Outlook
LNP screening is advancing toward higher throughput, greater precision and intelligent design. Three major breakthrough directions are anticipated: First, multi-technology integration. Deep fusion of microfluidic formulation, nucleic acid barcoding and single-cell sequencing will establish next-generation high-throughput screening platforms. Second, mechanistic deepening. Further dissection of molecular events including protein corona formation and endosomal escape will supply rigorous theoretical foundations for rational lipid engineering. Third, optimized clinical translation. Cross-species evaluation coupled with machine learning predictive modelling will curtail the scale and cost of in vivo experimentation and boost the bench-to-bedside translation rate of lead formulations.
As indispensable delivery vehicles for nucleic acid therapeutics, innovations in LNP screening technology will not only accelerate progress in gene therapy and vaccine development, but also unlock transformative therapeutic modalities for rare diseases, cancer and other intractable conditions, ushering in a new era of precision medicine.
